Freenome (FRNM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Aug, 2026Executive summary
An extraordinary general meeting is scheduled for June 10, 2026, to vote on extending the deadline to complete a business combination from June 13, 2026, to June 13, 2027, and to potentially adjourn the meeting if necessary.
The extension is sought to allow more time to complete a previously announced business combination with Freenome Holdings, Inc., though completion is not guaranteed.
Shareholders of record as of May 12, 2026, are eligible to vote and may attend in person or virtually.
Holders of Class A ordinary shares may redeem their shares for a pro rata portion of the trust account if the extension is approved.
Voting matters and shareholder proposals
Proposal 1: Amend the Memorandum and Articles of Association to extend the business combination deadline by one year.
Proposal 2: Adjourn the meeting if there are insufficient votes or excessive redemptions affecting Nasdaq listing requirements.
Both proposals require specific voting thresholds: two-thirds for the extension and a majority for adjournment.
The board unanimously recommends voting in favor of both proposals.
Board of directors and corporate governance
The board is led by Joseph Edelman (Chairman) and Adam Stone (CEO), with significant ownership by the sponsor and directors.
Initial shareholders, including directors and officers, hold approximately 22.1% of voting power and have agreed to vote in favor of the proposals.
The sponsor is affiliated with Perceptive Advisors, a major life sciences investment firm.
Latest events from Freenome
- IPO filing details a well-funded, AI-driven cancer screening innovator with FDA approval and major partnerships.FRNM
Registration filing - SPAC raised $86.25M, reports $1.91M net income, must acquire or liquidate in 24 months.FRNM
Q4 2024 - SPAC holds $91.9M in trust, targets Freenome merger in 2026, but faces going concern risks.FRNM
Q4 2025 - Q1 2025 net income reached $678,555, with $90.6M in assets and ongoing exposure to global market risks.FRNM
Q1 2025 - Q1 2026 saw a net loss and rising expenses as the company pursues the Freenome merger.FRNM
Q1 2026 - Q2 2025 net income reached $754,847, with ongoing risks tied to business combination completion.FRNM
Q2 2025 - Vote sought to extend merger deadline by one year; redemption rights and board support highlighted.FRNM
Proxy filing - Q3 net income reached $981,482, with all proceeds held in trust pending a business combination.FRNM
Q3 2024 - IPO completed, $86.25M raised; Q2 net income $102,875; business combination targeted by June 2026.FRNM
Q2 2024